Gruber S B, Entius M M, Petersen G M, Laken S J, Longo P A, Boyer R, Levin A M, Mujumdar U J, Trent J M, Kinzler K W, Vogelstein B, Hamilton S R, Polymeropoulos M H, Offerhaus G J, Giardiello F M
Division of Molecular Medicine and Genetics, University of Michigan, Ann Arbor 48109, USA.
Cancer Res. 1998 Dec 1;58(23):5267-70.
Peutz-Jeghers syndrome (PJS) is an autosomal dominant condition characterized by intestinal hamartomatous polyps, mucocutaneous melanin deposition, and increased risk of cancer. Families with PJS from the Johns Hopkins Polyposis Registry were studied to identify the molecular basis of this syndrome and to characterize the pathogenesis of gastrointestinal hamartomas and adenocarcinomas in PJS patients. Linkage analysis in the family originally described by Jeghers in 1949 and five other families confirmed linkage to 19p13.3 near a recently identified gene responsible for PJS. Germ-line mutations in this gene, STK11, were identified in all six families by sequencing genomic DNA. Analysis of hamartomas and adenocarcinomas from patients with PJS identified loss of heterozygosity (LOH) of 19p markers near STK11 in 70% of tumors. Haplotype analysis indicated that the retained allele carried a germ-line mutation, confirming that STK11 is a tumor suppressor gene. LOH of 17p and 18q was identified in an adenocarcinoma but not in hamartomas, implying that allelic loss of these two regions corresponds to late molecular events in the pathogenesis of cancer in PJS. The adenocarcinomas showing 17p LOH also demonstrated altered p53 by immunohistochemistry. None of the 18 PJS tumors showed microsatellite instability, LOH on 5q near APC, or mutations in codons 12 or 13 of the K-ras proto-oncogene. These data provide evidence that STK11 is a tumor suppressor gene that acts as an early gatekeeper regulating the development of hamartomas in PJS and suggest that hamartomas may be pathogenetic precursors of adenocarcinoma. Additional somatic mutational events underlie the progression of hamartomas to adenocarcinomas, and some of these somatic mutations are common to the later stages of tumor progression seen in the majority of colorectal carcinomas.
黑斑息肉综合征(PJS)是一种常染色体显性遗传病,其特征为肠道错构瘤性息肉、黏膜皮肤黑色素沉着以及癌症风险增加。对约翰霍普金斯息肉病登记处的PJS家族进行了研究,以确定该综合征的分子基础,并描述PJS患者胃肠道错构瘤和腺癌的发病机制。对1949年Jeghers最初描述的家族以及其他五个家族进行连锁分析,证实与19p13.3连锁,该区域靠近一个最近确定的与PJS相关的基因。通过对基因组DNA进行测序,在所有六个家族中均发现了该基因(STK11)的种系突变。对PJS患者的错构瘤和腺癌进行分析,发现在70%的肿瘤中,靠近STK11的19p标记存在杂合性缺失(LOH)。单倍型分析表明,保留的等位基因携带种系突变,证实STK11是一个肿瘤抑制基因。在一例腺癌中发现了17p和18q的LOH,但在错构瘤中未发现,这意味着这两个区域的等位基因缺失与PJS癌症发病机制中的晚期分子事件相对应。显示17p LOH的腺癌经免疫组织化学检测也显示p53改变。18例PJS肿瘤均未显示微卫星不稳定性、靠近APC的5q上的LOH或K-ras原癌基因第12或13密码子的突变。这些数据提供了证据,表明STK11是一个肿瘤抑制基因,作为早期守门人调节PJS中错构瘤的发展,并提示错构瘤可能是腺癌的发病前体。错构瘤向腺癌进展还存在其他体细胞突变事件,其中一些体细胞突变在大多数结直肠癌肿瘤进展的后期阶段是常见的。